Biodistribution Studies of Epithelial Cell Adhesion Molecule (EpCAM)-Directed Monoclonal Antibodies in the EpCAM-Transgenic Mouse Tumor Model1

@article{Kosterink2007BiodistributionSO,
  title={Biodistribution Studies of Epithelial Cell Adhesion Molecule (EpCAM)-Directed Monoclonal Antibodies in the EpCAM-Transgenic Mouse Tumor Model1},
  author={Jos G. W. Kosterink and Pamela M. J. McLaughlin and Marjolijn N. Lub-de Hooge and Harry H. Hendrikse and Jacoba van Zanten and Evert van Garderen and Martin Conrad Harmsen and L M de Leij},
  journal={The Journal of Immunology},
  year={2007},
  volume={179},
  pages={1362 - 1368}
}
The human pancarcinoma-associated epithelial cell adhesion molecule (EpCAM) (EGP-2, CO17-1A) is a well-known target for carcinoma-directed immunotherapy. Mouse-derived mAbs directed to EpCAM have been used to treat colon carcinoma patients showing well-tolerable toxic side effects but limited antitumor effects. Humanized or fully human anti-EpCAM mAbs may induce stronger antitumor activity, but proved to produce severe pancreatitis upon use in patients. To evaluate treatment-associated effects… 
View on Publisher
jimmunol.org
13 Citations
Background Citations
8

Figures and Tables from this paper

13 Citations

Citation Type

Citation Type

Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
TLDR
This preclinical study suggests that anti-EpCAM antibody conjugates with α-amanitin have the potential to be highly effective therapeutic agents for pancreatic carcinomas and various EpCAM-expressing malignancies.
The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm
TLDR
The findings highlight the need for extensive biodistribution studies of novel bispecific constructs, as the results might have implications for their respective drug development and clinical translation.
Comparison of mAbs Targeting Epithelial Cell Adhesion Molecule for the Detection of Prostate Cancer Lymph Node Metastases with Multimodal Contrast Agents: Quantitative Small-Animal PET/CT and NIRF
TLDR
Dual-labeled monoclonal antibodies of varying affinities against EpCAM are developed and quantitatively compared for both noninvasive and intraoperative detection of metastatic LNs in prostate cancer.
High Interstitial Fluid Pressure Is Associated with Low Tumour Penetration of Diagnostic Monoclonal Antibodies Applied for Molecular Imaging Purposes
TLDR
Investigation of the fine structure of the HT29 tumour blood vessels showed that they were immature and prone for higher fluid flux into the interstitial space, which could explain the limited diffusion of the antibody into the tumour observed by immunohistochemistry.
Optical Imaging of Cellular Immunotherapy against Prostate Cancer
TLDR
Track fluorophore-labeled, tumor-targeted natural killer cells to human prostate cancer xenografts with optical imaging (OI) confirmed a specific accumulation of NK-92-scFv(MOC31)-zeta cells but not parental NK cells in the tumors.
Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death
TLDR
Targeted delivery ofCD40L to cancer cells is a promising strategy that may help to trigger cancer-localized activation of CD40 and can be modified to exert additional anti-cancer activity via the targeting domain.
Targeted delivery of CD 40 L promotes restricted activation of antigen-presenting cells and induction of cancer cell
TLDR
Targeted delivery ofCD40L to cancer cells is a promising strategy that may help to trigger cancer-localized activation of CD40 and can be modified to exert additional anti-cancer activity via the targeting domain.
Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology.
TLDR
A number of case studies are presented that demonstrate the utility of biodistribution studies during preclinical development of biotherapeutics for non oncology indications, as well as provide a practical perspective on the methodology applied.
Stage-specific regulation of adhesion molecule expression segregates epithelial stem/progenitor cells in fetal and adult human livers
TLDR
Regulated expression of Ep-CAM supported proliferation in fetal hepatoblasts through weak adhesion and helped in biliary morphogenesis by promoting stronger adhesion in hepatoblast during this process.
Monitoring of New Immunotherapies for Prostate Cancer with Optical Imaging
TLDR
A significant increase in tumor fluorescence at 24 hours post injection of tumor-target NK cells was observed in contrast to parental NK-92 cells, confirming the cytotoxicity of genetically modified natural killer cells in comparison to non-targeted natural killers.
...
1
2
...

References

SHOWING 1-10 OF 37 REFERENCES
Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
TLDR
Compared to a previous study, the present protocol did not augment the overall or progression-free survival, and further studies are warranted to establish the role of EpCAM as a target for antibody therapy, specifically the significance of chimeric or humanized anti-EpCAM MAbs.
Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies.
TLDR
The results of the present study indicate that 17-1A chimeric IgG1 antibody may be the best choice for clinicalRadioimmunodetection and radioimmunotherapy studies.
An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy
TLDR
An EGP-2-transgenic rat model has been generated that serves as a model to evaluate the efficacy and safety of a variety of anti-EGP- 2-based immunotherapeutic modalities and to evaluate treatment-associated effects and side-effects on tumor and normal tissue respectively.
In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule.
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment
TLDR
The fully human nature and the improved ADCC of MT201 with human effector cells will make MT201 a promising candidate for the clinical development of a novel pan‐carcinoma antibody that is superior to edrecolomab.
New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency.
TLDR
The superior reactivity of chimeric 323/A3 with EGP40 on carcinoma cells and its higher cytotoxicity-mediating capacity, compared to chimeric 17-1A are important characteristics, which support further clinical studies with chimeric MAb 323/ a3 in immunotherapy of carcinomas.
Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.
TLDR
It is described that T-cell-activating superantigens targeted to a tumor by monoclonal antibodies induced large numbers of pseudospecific TILs and eradication of micrometastases.
Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo
TLDR
It is described that T-cell-activating superantigens targeted to a tumor by monoclonal antibodies induced large numbers of pseudospecific TILs and eradication of micrometastases.
Expression of an antigen homologous to the human CO17-1A/GA733 colon cancer antigen in animal tissues.
TLDR
The antigen homologue expressed by animal tissues is similar, but not identical, to the human antigen, which has important implications for experimental active and passive immunotherapy targeting the CO17-1A/GA733 antigen.
The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy.
TLDR
An E GP-2 transgenic mouse model has been generated that expresses the EGP-2 antigen as in humans and, therefore, can serve as a model to evaluate the efficacy and safety of a variety of anti-EGP-2-based immunotherapeutic modalities in both tumors and normal tissue.
...
1
2
3
4
...